Skip to main content

Profiles

CSL Seqirus

CSL Seqirus, formerly Seqirus, is an Australian multinational vaccine development company. It is a subsidiary of CSL Limited.

History

Seqirus was an exhibitor and sponsor for the OPTIONS IX for the Control of Influenza conference from August 24-28, 2016, in Chicago, Illinois,[1][2] and the Canadian Immunization Conference 2016 from December 6-8, 2016, in Ottawa, Ontario.[3]

Seqirus was a sponsor for the Canadian Immunization Conference 2018 from December 4-6, 2018, at the Shaw Centre in Ottawa, Ontario.[4]

Seqirus was a sponsor for the OPTIONS X for the Control of Influenza conference from August 26-September 1, 2019, in Singapore.[5]

COVID-19

Seqirus was a sponsor for the 2021 AMMI Canada - CACMID Annual Conference,[6] the Canadian Immunization Conference 2021[7] and the 2022 British Columbia Pharmacy Association Annual Conference.[8]

On August 26, 2022, CSL announced that Seqirus was being renamed CSL Seqirus.[9]

CSL Seqirus was an exhibitor and event sponsor at OPTIONS XI for the Control of Influenza from September 26-29, 2022, in Belfast, England.[10][11]

On May 30, 2024, CSL Seqirus announced that it had been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to deliver 4.8 million doses of its H5N1 vaccine for the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program, its fourth such award.[12] On June 11, the company announced a similar award from the European Commission for 665,000 doses for the Health Emergency Preparedness and Response Authority (HERA).[13]

Organization

Seqirus is a member organization of the Adult Vaccine Access Coalition,[14] Alliance for Biosecurity,[15] BIOTECanada[16] the Biotechnology Innovation Organization (BIO)[17] the European Federation of Pharmaceutical Industries and Associations (EFPIA)[18] and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA),[19] and a partner organization of Global Health Progress[20] and the National Foundation for Infectious Diseases (NFID).[21]

Personnel

Name Position Notes
Kristina Bradford Senior Project Manager[22] BARDA Industry Day 2018
Randy Deck Senior Director, Pandemic Contracts[22:1] BARDA Industry Day 2018
Phyllis Frosst Global Director, Health Policy[22:2] BARDA Industry Day 2018
Marie Mazur Vice President, Pandemic Response Solutions[22:3] BARDA Industry Day 2018
Melissa Puryear Legal Counsel[22:4] BARDA Industry Day 2018
Martina Scionti Senior Manager, Strategic Planning[22:5] BARDA Industry Day 2018
Gillian Talley Head of Batch Release[22:6] BARDA Industry Day 2018
Beverly Taylor Head of Global Influenza Scientific Policy[23] Multivalent COVID vaccines to help address emergence of variants: CMC and clinical implications

Activities

CSL Seqirus has provided funding to:

  1. OPTIONS IX Supporters. OPTIONS IX. Retrieved July 7, 2017, from https://web.archive.org/web/20170707010655/http://2016.isirv.org/options-ix-supporters ↩︎

  2. Exhibit Opportunities. Options IX. Retrieved July 6, 2017, from https://web.archive.org/web/20170706213219/http://2016.isirv.org/exhibit-opportunities ↩︎

  3. Final Program. (2016, December 6). Canadian Immunization Conference. https://web.archive.org/web/20220320171400/https://www.cpha.ca/sites/default/files/uploads/conferences/2021/cic16-final-program-en.pdf ↩︎

  4. CIC 2018 Final Program. (2018, November). Canadian Immunization Conference. https://web.archive.org/web/20220320193739/https://cic-cci.ca/wp-content/uploads/2018/11/CIC-2018-Final-Program.pdf ↩︎

  5. Options X Supporters. ISIRV 2019. Retrieved October 27, 2022, from https://web.archive.org/web/20221027005431/https://2019.isirv.org/options-x-supporters ↩︎

  6. Sponsorship & Exhibitor Prospectus. (2021, December). Association of Medical Microbiology and Infectious Diseases Canada. https://web.archive.org/web/20230430042311/https://ammi.ca/wp-content/uploads/2021/12/2022-Sponsorship-.Exhibitor-ProspectusFINAL.pdf ↩︎

  7. CIC 2021 Final Program. (2021). Canadian Public Health Association. https://web.archive.org/web/20220422103306/https://www.cpha.ca/sites/default/files/uploads/conferences/2021/cic21-program.pdf ↩︎

  8. Our Sponsors and Prizes. British Columbia Pharmacy Association. Retrieved May 22, 2022, from http://archive.today/2022.05.23-043337/https://www.bcpharmacy.ca/conference/prizes/2022 ↩︎

  9. Coey, S. K. (2022, August 26). CSL to unite all business units, including Seqirus, under the CSL umbrella. Fierce Pharma. https://web.archive.org/web/20220826150412/https://www.fiercepharma.com/marketing/csl-unite-all-business-unit-including-seqirus-under-one-csl-umbrella ↩︎

  10. Meet the Exhibitors. OPTIONS XI. Retrieved October 26, 2022, from https://web.archive.org/web/20221026234139/https://www.optionsxi2022.org.uk/exhibition-and-sponsors2/meet-the-exhibitors ↩︎

  11. Main Sponsors & Supporters. OPTIONS XI. Retrieved October 26, 2022, from https://web.archive.org/web/20221026234119/https://www.optionsxi2022.org.uk/exhibition-and-sponsors2/main-sponsors-and-supporters ↩︎

  12. Dunleavy, K. (2024, May 30). CSL Seqirus scores 4th award from US government for bird flu pandemic preparedness. Fierce Pharma. https://web.archive.org/web/20240812134158/https://www.fiercepharma.com/pharma/csl-seqirus-scores-4th-award-us-government-bird-flu-pandemic-preparedness ↩︎

  13. CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU. (2024, June 11). CSL. https://web.archive.org/web/20240804012948/https://newsroom.csl.com/2024-06-11-CSL-Seqirus,-a-Proud-Champion-of-Pandemic-Preparedness,-Signs-an-Agreement-with-the-European-Commission-to-Provide-Pre-Pandemic-Vaccines-to-the-EU ↩︎

  14. AVAC Member Organizations. (2021). Adult Vaccine Access Coalition. http://archive.today/2022.07.08-060340/https://adultvaccinesnow.org/our-membership/avac-member-organizations/ ↩︎

  15. Who We Are. Alliance for Biosecurity. Retrieved June 21, 2022, from http://archive.today/2022.06.21-000415/https://web.archive.org/web/20200812033301/https://www.allianceforbiosecurity.com/who-we-are ↩︎

  16. Member Listings. BIOTECanada. Retrieved August 6, 2024, from https://web.archive.org/web/20240806080411/https://www.biotech.ca/about/member-listings/ ↩︎

  17. BIO Member Directory. Biotechnology Innovation Organization. Retrieved September 30, 2022, from https://web.archive.org/web/20220930103715/https://www.bio.org/bio-member-directory ↩︎

  18. Membership. (2022). European Federation of Pharmaceutical Industries and Association. https://web.archive.org/web/20220701031757/https://www.efpia.eu/about-us/membership/ ↩︎

  19. Companies. IFPMA. Retrieved July 1, 2022, from https://web.archive.org/web/20220701150736/https://www.ifpma.org/who-we-are/our-membership/full-members/companies/ ↩︎

  20. Explore Our Collaborations. (2022). Global Health Progress. https://web.archive.org/web/20220403013206/https://globalhealthprogress.org/explore-our-collaborations/ ↩︎

  21. NFID Partner Organizations. (2022, January 6). National Foundation for Infectious Diseases. https://web.archive.org/web/20220716065253/https://www.nfid.org/partners/ ↩︎

  22. BARDA Industry Day 2018 Post Conference Participant List. Biomedical Advanced Research and Development Authority. Retrieved February 27, 2023, from https://web.archive.org/web/20230227080444/https://www.medicalcountermeasures.gov/BARDA/documents/BID2018_ParticipantList.pdf ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  23. Granerod, J. (2021, April 14). Workshop Report: COVAX Manufacturing and Clinical Development SWAT Teams Workshop on “Multivalent COVID vaccines to help address emergence of variants: CMC and clinical implications.” The Global Health Network. https://web.archive.org/web/20230322033935/https://media.tghn.org/medialibrary/2021/04/COVAX_VDM_CD_SWAT_TEAM_Workshop_20210414_Multivalent_Vaccines_FINAL_REPORT.pdf ↩︎

  24. How We’re Funded. (2022). Alliance for Aging Research. https://web.archive.org/web/20220715161317/https://www.agingresearch.org/about-us/how-were-funded/ ↩︎

  25. Chung, H., Buchan, S. A., Campigotto, A., Campitelli, M. A., Crowcroft, N. S., Dubey, V., Gubbay, J. B., Karnauchow, T., Katz, K., McGeer, A. J., McNally, J. D., Mubareka, S., Murti, M., Richardson, D. C., Rosella, L. C., Schwartz, K. L., Smieja, M., Zahariadis, G., & Kwong, J. C. (2020). Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010–2011 to 2015–2016 Seasons in Ontario, Canada. Clinical Infectious Diseases, 73(5), e1191–e1199. https://doi.org/10.1093/cid/ciaa1862 ↩︎

  26. Corporate partners. Canadian Public Health Association. Retrieved April 19, 2024, from https://web.archive.org/web/20240419085756/https://www.cpha.ca/corporate-partners ↩︎

  27. New Modelling Study concludes “Unvaccinated are a danger to the Vaccinated”; but Real-World Data proves COVID Vaccines INCREASE Risk of Infection by 400%. (2022, April 29). The Exposé. https://web.archive.org/web/20220511165651/https://expose-news.com/2022/04/29/covid-jabs-increase-risk-infection-400percent/ ↩︎

  28. Our Partners in Preventing Influenza. Families Fighting Flu. Retrieved August 1, 2024, from https://web.archive.org/web/20240801141143/https://www.familiesfightingflu.org/donors-sponsors/ ↩︎

  29. The Foundation for Influenza Epidemiology. Global Influenza Hospital Surveillance Network. Retrieved March 28, 2022, from http://archive.today/2022.03.28-193124/https://www.gihsn.org/about-us/the-foundation-for-influenza-epidemiology ↩︎

  30. About Us. Immunisation Coalition. Retrieved December 5, 2021, from https://web.archive.org/web/20210303185121/https://www.immunisationcoalition.org.au/about-us/ ↩︎

  31. Member Organizations. Immunize Canada. Retrieved July 19, 2024, from https://web.archive.org/web/20240719141916/https://immunize.ca/member-organizations ↩︎

  32. Permar, S., Creech, C. B., Edwards, K. M., & Walter, E. B. (2021). Proposals to Accelerate Novel Vaccine Development for Children. Pediatrics, 149(1). https://doi.org/10.1542/peds.2021-054593 ↩︎

  33. Our Partners. Lung Health Foundation. Retrieved June 9, 2022, from http://archive.today/2022.06.09-004346/https://lunghealth.ca/our-partners/ ↩︎

  34. Evans, T., Sadarangani, M., Maguire, J., Zinszer, K., & Kellner, J. (2022). The importance of pediatric vaccination. COVID-19 Immunity Task Force. https://web.archive.org/web/20220424080020/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2022/03/CITF_CanCOVID_6_Pediatric-vaccination_2022_EN_FINAL-2.pdf ↩︎

  35. Waite, N. M., Pereira, J. A., Houle, S. K. D., Gilca, V., & Andrew, M. K. (2021). COVID-19’s impact on willingness to be vaccinated against influenza and COVID-19 during the 2020/2021 season: results from an online survey of Canadian adults 50 years and older. Vaccines, 9(4), 346. https://doi.org/10.3390/vaccines9040346 ↩︎

  36. Lee, N. (2018). ICMJE Form for Disclosure of Potential Conflicts of Interest (pp. 24–26). New England Journal of Medicine. https://web.archive.org/web/20220511231133/https://www.nejm.org/doi/suppl/10.1056/NEJMoa1716197/suppl_file/nejmoa1716197_disclosures.pdf ↩︎

  37. Conflicts of Interest in Pfizer Vaccine Trial. (2022, April 12). ICAN - Informed Consent Action Network. http://archive.today/2022.04.12-231318/https://www.icandecide.org/ican_press/conflicts-of-interest-in-pfizer-vaccine-trial/ ↩︎

  38. Coleman, B. L., Sanderson, R., Haag, M. D. M., & McGovern, I. (2021). Reply to Letter to the Editor by Yin et al. Influenza and Other Respiratory Viruses, 15(6), 828–829. https://doi.org/10.1111/irv.12895 ↩︎

  39. Annual Report 2021. The Task Force for Global Health. Retrieved April 20, 2022, from https://web.archive.org/web/20220215172458/https://www.taskforce.org/annual-report-2021/#section_2 ↩︎

  40. About Us. Vaccines4Life. Retrieved July 15, 2022, from https://web.archive.org/web/20220715204513/https://www.vaccines4life.com/about-us/ ↩︎

  41. Voluntary contributions by fund and by contributor, 2021. (2022). World Health Organization. https://web.archive.org/web/20220516042059/https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_INF5-en.pdf ↩︎